Teva’s Adderall makes it off the FDA shortage list while generic ADHD med supply squeeze persists

 ADHD in the News 2024-05-23


In a welcome respite from the persistent nationwide Adderall shortage, Teva seems to have gotten a handle on its supply. The drugmaker has all of its Adderall products marked as available on the FDA’s shortage list, except for the 5-mg version of its generic offering, which is estimated to see supply recovery in June.

View Article: Fierce Pharma, May 22, 2024




Other Articles in this Edition

ADHD diagnoses are rising. 1 in 9 U.S. kids have gotten one, new study finds

Doctors Are Still Figuring Out Adult A.D.H.D.

ADHD drug shortage shows signs of letting up, but some patients still struggle

Teva’s Adderall makes it off the FDA shortage list while generic ADHD med supply squeeze persists

ADHD Treatment Linked to Higher Long-Term Risk for Stroke and Heart Failure

One in two children with ADHD experience emotional problems, study finds

Transitional Neonatal Hypoglycemia Tied to Adverse Neurodevelopmental Outcomes

‘A Unique Challenge’: What English Learners With Disabilities Need

Short Sleep Increases Obesity Risk Among Adolescents With Unmedicated ADHD

FDA Clears Cingulate to File NDA for CTx-1301 in the Treatment of ADHD

Virtual Gaming May Enhance Working Memory for Youth With ADHD

Scientists find link between ADHD and gaming disorder in college students

Understanding Primary and Associated Symptoms in Adult ADHD